Here is the latest stock price and chart of DR HABEEBULLAH LIFE SCIENCES. For more details, see the DR HABEEBULLAH LIFE SCIENCES company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Alert: Discover the Makings of Potential 'Crorepati' Stocks from Richa Agarwal
Live BSE Quotes | May 20, 2022 (Close) | ||
---|---|---|---|
Price (Rs)25.40 | Open (Rs) 26.50 | High (Rs) 26.50 | Low (Rs) 25.20 |
% Change1.60 | Volume 3,435 | Value (Rs) 87,456 | 52-Week H/L 44.15 / 22.80 |
Live NSE Quotes |
---|
Not listed |
Change | |||||
---|---|---|---|---|---|
1 Day 1.60% | 1 Month -5.75% | 3 Months -16.45% | 1 Year -26.16% |
Valuation | ||||
---|---|---|---|---|
EPS (Rs)* -0.06 | P/E Ratio (x) NM | Market Cap (Rs m) 376.14 | P/BV (x) 3.37 | Dividend Yield (%) 0.00 |
*Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
![]() |
||
S&P BSE SENSEX ![]() |
||||||
PERIOD |
DR HABEEBULLAH LIFE SCIENCES last traded price was up 1.6% to Rs 25.4 on the BSE. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 3.0%. And the benchmark S&P BSE SENSEX was at 54,326.4 (up 2.9%).
Over the last 30 days, the DR HABEEBULLAH LIFE SCIENCES share price is down 4.2%. And over the last one year, DR HABEEBULLAH LIFE SCIENCES share price is down 29.8%.
The current market capitalisation of DR HABEEBULLAH LIFE SCIENCES stands at Rs 376.14 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of March 2022, company promoters held 52.87% stake in DR HABEEBULLAH LIFE SCIENCES, with no shares having been pledged. To know more, check out the latest shareholding pattern of DR HABEEBULLAH LIFE SCIENCES.
What else is happening in the markets today? Dig in...
Bulls marked a strong comeback today as Indian share markets ended nearly 3% higher. After opening the day higher, equity markets extended gains as the session progressed and ended near the day's high.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.
In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More